Alcon Inc. ALC
74.06 USD -1.08 (-1.44%)
At closeNov 10, 2026, 7:59 PM EST
70.00 -4.06 -5.48%
After hours · Nov 10, 7:59 PM ET
72.21 Day range 75.71
61.84 52-week range 87.64
- YTD
- -6.03%
- 1 year
- -0.44%
News
zacks.com Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare…
benzinga.com CORRECTION: Alcon Q3 Adj. EPS $0.91 Beats $0.87 Estimate, Sales $2.717B Miss $2.737B Estimate Alcon (NYSE:ALC) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.87 by 4.6 percent. This is a 15.19 percent increase over earnings of $0.79 per share…
benzinga.com Alcon Narrows FY2026 Adj EPS Guidance from $3.44-$3.53 to $3.44-$3.50 vs $3.44 Est; Narrows FY2026 Sales Guidance from $10.835B-$11.041B to $10.938B vs $11.073B Est Alcon (NYSE:ALC) narrows FY2026 Adj EPS guidance from $3.44-$3.53 to $3.44-$3.50 vs $3.44 analyst estimate. Narrows FY2026 sales outlook from $10.835 billion-$11.041 billion to $10.938 billion vs…
benzinga.com Alcon Q3 Adj. EPS $0.91 Beats $0.87 Estimate, Sales $2.717M Miss $2.737B Estimate Alcon (NYSE:ALC) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.87 by 4.6 percent. This is a 15.19 percent increase over earnings of $0.79 per share…
benzinga.com TransDigm Group, Take-Two And 3 Stocks To Watch Heading Into Tuesday Stocks in focus: TransDigm and Sally Beauty report earnings; Babcock & Wilcox beat sales; Take-Two topped estimates; Alcon reports after close.
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…
businesswire.com Algoma Central Corporation Announces Closing of Over-Allotment Option of Additional Debentures ST. CATHARINES, Ontario--(BUSINESS WIRE)--Algoma Central Corporation (“Algoma”) (TSX:ALC) is pleased to announce that, in connection with its previously announced offering (the “Public Offering”) of…
businesswire.com Algoma Central Corporation Reports Financial Results for the 2026 Third Quarter ST. CATHARINES, Ontario--(BUSINESS WIRE)--Algoma Central Corporation (TSX: ALC) ("Algoma", the "Company") today reported its results for the three and nine months ended September 30, 2026. Algoma…
zacks.com Countdown to Alcon (ALC) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS Beyond analysts' top-and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter…
zacks.com Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains? Alcon (ALC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
seekingalpha.com Higher Margins, Better ROIC And Capable Management Define Pershing Square's Q3 2026 Portfolio We seek to purchase our target companies at share prices that incorporate a margin of safety. We estimate that the companies in PSH's investment portfolio will have average annual EPS growth of about…- benzinga.com Keybanc Maintains Overweight on Alcon, Lowers Price Target to $84 Keybanc analyst Brett Fishbin maintains Alcon (NYSE:ALC) with a Overweight and lowers the price target from $88 to $84.
seekingalpha.com Alcon Sees Another Bullish Rating After Clear Portfolio Growth Direction In Eyecare Alcon Inc. remains a Buy, supported by FDA approvals, portfolio-expanding acquisitions, and robust long-term eyecare demand despite recent market underperformance. ALC demonstrates steady revenue…
benzinga.com Alcon Acquires Neurotech Pharmaceuticals For $550M Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company focused on developing…
businesswire.com Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2 GENEVA--(BUSINESS WIRE)--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2.
globenewswire.com Algoma Central Corporation Announces $62.5 million Offering of 6.20% Convertible Unsecured Subordinated Debentures CATHARINES, ONTARIO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Algoma Central Corporation (“Algoma”) (TSX:ALC) announced today that it has entered into an agreement to sell, on a bought deal basis to a…
businesswire.com FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.- benzinga.com Alcon Announces FDA Approval For BRYTLY Redness Relief Eye Drops, Expanding Over The Counter Eye Care Portfolio. One drop works to significantly reduce redness, with results lasting up to 12 hours1Lasts up to 50% longer than Lumify1-2,*Expands Alcon's portfolio of consumer eye care solutions and will be…
businesswire.com FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
zacks.com Credo Expands AI Connectivity Portfolio With 1.6T ZeroFlap ALC CRDO expands its AI connectivity portfolio with the 1.6T ZeroFlap Active Light Cable, offering lower power consumption, enhanced reliability and extended reach.
gurufocus.com Credo Unveils 1.6T ZeroFlap Active Light Cable, Industry's First Row-Scale, Wide-Parallel Optical Interconnect for AI Data Centers [url="]Credo Technology Group Holding Ltd[/url] (Credo) (NASDAQ: CRDO), an innovator in providing connectivity at scale through fast, reliable, and energy-effic
benzinga.com Barclays Initiates Coverage On Alcon with Equal-Weight Rating, Announces Price Target of $70 Barclays analyst Christopher Pasquale initiates coverage on Alcon (NYSE:ALC) with a Equal-Weight rating and announces Price Target of $70.
defenseworld.net Algoma Central (TSE:ALC) Shares Cross Above 50 Day Moving Average – Here’s Why Algoma Central Co. (TSE: ALC - Get Free Report) passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of C$23.31 and traded as high as C$23.99.…
zacks.com Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now? Alcon's acquisitions, partnerships and new product launches support growth, but tariffs and intense competition remain key risks.
seekingalpha.com Alcon: A Re-Rating In Eyesight Alcon is a structurally advantaged ophthalmology leader with a durable equipment-to-consumables model and strong recurring revenue streams. At $72, ALC trades at ~18x forward earnings, reflecting…
businesswire.com Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control GENEVA--(BUSINESS WIRE)--Alcon Launches UNITY® M, a Premium Ophthalmic Microscope Delivering Precise Control.
benzinga.com Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
businesswire.com Alcon Prices EUR 500 Million Senior Notes Offering GENEVA--(BUSINESS WIRE)--Alcon Prices EUR 500 Million Senior Notes Offering.
benzinga.com Why Is Netflix Stock Falling on Monday? Netflix Inc. (NASDAQ: NFLX) stock slips as market concerns over third-quarter revenue and earnings guidance outweigh Bill Ackman's new Pershing Square stake.
seekingalpha.com Alcon: A Strong Company Trading Close To Its Intrinsic Value, Buy Alcon reported strong core operating profit (barring a one-time non-cash $402 million charge) during the quarter, up 17%. The company raised its full-year 2026 profit forecast for the second…
fool.com Bill Ackman Just Disclosed 6 New Positions, and 4 of Them Are Financial Stocks. Here's What He's Betting On. The famous long-term investor and his team made notable changes to Pershing Square's equity portfolio.
benzinga.com Bill Ackman’s New Stock Picks Are Here. These ETFs Could Be Worth Watching Bill Ackman's new stock picks include Netflix, Visa and Mastercard. ETF investors can get fresh exposure through VFH, XLC and IAI.
benzinga.com Bill Ackman Lost $400 Million on NFLX Stock in 2022 — Now He’s Back With a 3.15M-Share Bet, Saying Netflix Has ‘Won the Streaming Wars’ (UPDATED) Bill Ackman’s Pershing Square re-enters Netflix with a 3.15M share stake, declaring the streaming wars won after a historic 2022 loss.
benzinga.com JP Morgan Maintains Neutral on Alcon, Raises Price Target to $78.4 JP Morgan analyst David Adlington maintains Alcon (NYSE:ALC) with a Neutral and raises the price target from $77.53 to $78.4.
benzinga.com Mizuho Maintains Outperform on Alcon, Raises Price Target to $85 Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Outperform and raises the price target from $80 to $85.
benzinga.com National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…- benzinga.com Alcon Raises FY2026 Adj EPS Guidance from $3.38-$3.47 to $3.44-$3.53 vs $3.41 Est; Widens FY2026 Sales Guidance of $10.835B-$11.041B vs $11.087B Est Alcon (NYSE:ALC) raises FY2026 Adj EPS guidance from $3.38-$3.47 to $3.44-$3.53 vs $3.41 analyst estimate. Widens FY2026 sales outlook from $10.835 billion-$11.041 billion to $10.835 billion-$11.041…
benzinga.com Alcon Q2 Adj. EPS $0.84 Beats $0.75 Estimate, Sales $2.782B Beat $2.769B Estimate Alcon (NYSE:ALC) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.75 by 12 percent. This is a 10.53 percent increase over earnings of $0.76 per share…
benzinga.com S&P 500 Surges To Record Close Following Jobs Data: Investor Sentiment Improves, Fear Index Remains in ‘Greed’ Zone U.S. stocks closed higher, with Nasdaq up 300 points. S&P 500 and Nasdaq rose for the second consecutive week. Fear & Greed index in Greed zone.
benzinga.com Aecom, Alcon And 3 Stocks To Watch Heading Into Monday U.S. stock futures mixed, Aecom and Hawaiian Electric report earnings, Alcon expected to release earnings, Check Cap announces reverse split, Monday.Com expected to post earnings.- benzinga.com Mizuho Maintains Outperform on Alcon, Lowers Price Target to $80 Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $85 to $80.
- benzinga.com Alcon And RxSight Announce A Non-Exclusive Collaboration To Jointly Develop Adjustable Presbyopia-Correcting Intraocular Lenses Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality…
benzinga.com Zoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio? Weak earnings, soft guidance and analyst target cuts triggered sharp selloffs across healthcare, software, networking and industrial stocks last week, led by Zoetis, Insmed and HubSpot.
benzinga.com Barclays Maintains Equal-Weight on Alcon, Lowers Price Target to $78 Barclays analyst Matt Miksic maintains Alcon (NYSE:ALC) with a Equal-Weight and lowers the price target from $90 to $78.- benzinga.com Wells Fargo Maintains Overweight on Alcon, Lowers Price Target to $86 Wells Fargo analyst Larry Biegelsen maintains Alcon (NYSE:ALC) with a Overweight and lowers the price target from $97 to $86.
- benzinga.com Mizuho Maintains Outperform on Alcon, Lowers Price Target to $85 Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $95 to $85.
- benzinga.com Baird Maintains Outperform on Alcon, Lowers Price Target to $90 Baird analyst Jeff Johnson maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $98 to $90.
- benzinga.com Alcon Q1 2026 Earnings Call Transcript
benzinga.com Earnings Scheduled For May 5, 2026